SEATTLE and COPHENHAGEN, Denmark, April 2, 2014 /PRNewswire/ -- CMC Biologics, a leading global contract manufacturing organization known for technical excellence and customer satisfaction in biopharmaceutical development and commercial manufacture of protein based therapeutics, was recognized again in 2014 for innovation, quality and reliability by Life Science Leader at an awards ceremony at DCAT Week14 in New York last month.
Logo - http://photos.prnewswire.com/prnh/20110502/SF93356LOGO
"The entire CMC Biologics' team is honored to receive this prestigious award as recognition from our customers and the industry as a whole. Our goal is to provide our customers with the highest standards of quality and reliability, which is the foundation of their clinical and commercial success," said Gustavo Mahler, PhD, Chief Operations Officer. "We are committed to continuous innovation of our facility, and to growing and supporting our most critical asset—our people at all levels of the organization—to advance biopharmaceutical manufacturing to the next level."
View an exclusive interview at the ceremony with COO Gustavo Mahler here: http://youtu.be/BmcNKd23kN8.
Bringing new pharmaceutical products to market is time consuming and costly, thereby having reliable and effective contract organizations to work with helps streamline that process. The Life Science Leader CMO Leadership awards are designed to honor top performers based on survey responses from thousands of industry executives, conducted by Nice Insight, and to better serve biopharmaceutical executives in their CMO selection process. These data will help companies focus on potential CMO partners who can handle their projects and are considered most reputable in the industry.
About CMC Biologics
CMC Biologics is leading the industry among CMO's in reliability, technical excellence, and quality – Right and On Time. With facilities in the USA and Europe, the Company is a global CMO that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.
Del denne artikel